Gaudium IVF & Women Health Share Price | Gaudium IVF & Women Health Stock Screener
GAUDIUMIVF
Healthcare Service Provider
Share Price NSE
₹124.39
▼
-1.08 (-0.86%)
Share Price BSE
₹116.65
▲
4.10 (3.64%)
As of April 24, 2026, the Gaudium IVF & Women Health share price (NSE: GAUDIUMIVF) is ₹124.39 on NSE and ₹116.65 on BSE, down 0.86% from the previous close, with shares trading between ₹118.25 and ₹133.00, and a 52-week range of ₹70.67–₹125.47.
Check GAUDIUMIVF yearly price range for the annual price range and momentum.
Use the Gaudium IVF & Women Health stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Gaudium IVF & Women Health Market Cap
₹747.89 Cr.
GAUDIUMIVF P/E Ratio (TTM)
34.41
Gaudium IVF & Women Health P/B Ratio
5.25
EPS (TTM)
₹3.12
Dividend Yield
-
Debt to Equity
0.52
GAUDIUMIVF 52 Week High
₹125.47
Gaudium IVF & Women Health 52 Week Low
₹70.67
Operating Margin
33.00%
Profit Margin
25.93%
GAUDIUMIVF Revenue (TTM)
₹27.00
EBITDA
₹9.00
Net Income
₹7.00
Total Assets
₹89.00
Total Equity
₹46.00
Gaudium IVF & Women Health Share Price Chart
Screen Gaudium IVF & Women Health share price with an interactive chart. Analyse GAUDIUMIVF price trends and volatility across different timeframes.
Gaudium IVF & Women Health Company Profile - Fundamental Screener
Screen Gaudium IVF & Women Health company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GAUDIUMIVF shares.
Sector
Healthcare
Industry
Healthcare Service Provider
Sub-Sector
Healthcare Service Provider
Segment
E
ISIN
INE0P8B01020
Gaudium IVF & Women Health Balance Sheet Screener
Screen GAUDIUMIVF balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Total Assets | 89 | 57 | 37 | 18 |
| Current Assets | 54 | 38 | 18 | 14 |
| Fixed Assets | 18 | 19 | 18 | 4 |
| Liabilities | ||||
| Total Liabilities | 0 | 0 | 0 | 0 |
| Current Liabilities | 4 | 4 | 4 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||
| Total Equity | 46 | 33 | 23 | 9 |
| Share Capital | 31 | 1 | 1 | 1 |
| Reserves & Surplus | 16 | 32 | 22 | 8 |
Gaudium IVF & Women Health Income Statement Screener - Profit & Revenue Analysis
Screen Gaudium IVF & Women Health income statement and profit fundamentals.
Analyze GAUDIUMIVF quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Gaudium IVF & Women Health share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Dec |
|---|---|---|---|---|---|
| Revenue | 27 | 18 | 32 | 25 | 14 |
| Expenses | 18 | 13 | 18 | 18 | 9 |
| EBITDA | 9 | 5 | 14 | 7 | 6 |
| Operating Profit % | 33.00% | 29.00% | 43.00% | 27.00% | 39.00% |
| Depreciation | 0 | 1 | 1 | 1 | 1 |
| Interest | 0 | 1 | 1 | 1 | 0 |
| Profit Before Tax | 8 | 4 | 13 | 5 | 5 |
| Tax | 2 | 1 | 3 | 1 | 1 |
| Net Profit | 7 | 3 | 9 | 4 | 3 |
| EPS | 1.07 | 0.51 | 1.53 | 0.59 | 0.55 |
Gaudium IVF & Women Health Cash Flow Screener - Liquidity Fundamentals
Screen GAUDIUMIVF cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Operating Activities | 9 | 3 | 24 | -1 |
| Investing Activities | -15 | -5 | -16 | -1 |
| Financing Activities | 2 | -1 | 5 | 3 |
| Net Cash Flow | -5 | -3 | 14 | 0 |
Gaudium IVF & Women Health Shareholding Pattern Screener
See Gaudium IVF & Women Health shareholding pattern with promoter, FII, and DII holdings.
Check Gaudium IVF & Women Health promoter holding and ownership changes for GAUDIUMIVF on TickJournal.
| Item | 2026-Feb | 2026-Mar | 2025-Jan | 2025-Sept |
|---|---|---|---|---|
| Promoter Holding | 71.29% | 71.29% | 99.98% | 99.98% |
| FII Holding | 9.24% | 6.70% | 0.00% | 0.00% |
| DII Holding | 5.11% | 2.62% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.52% | 14.67% | 0.00% | 0.00% |
| Other Holding | 0.84% | 4.73% | 0.02% | 0.02% |
| Shareholder Count | 7 | 19,854 | 7 | 7 |
Gaudium IVF & Women Health Share Dividend Screener - Share Yield Analysis
Check Gaudium IVF & Women Health dividend history with payout and yield data.
View Gaudium IVF & Women Health dividend details including ex-dates and amounts for GAUDIUMIVF stock.
Gaudium IVF & Women Health Stock Index Membership
See which indices include Gaudium IVF & Women Health stock.
Check GAUDIUMIVF index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Gaudium IVF & Women Health Market Events Screener - Corporate Actions
Get Gaudium IVF & Women Health corporate actions including splits, bonuses, and buybacks.
Check Gaudium IVF & Women Health stock events that may affect GAUDIUMIVF share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-03-18 | 2026-03-18 | Quarterly Result Announcement | NA | 5.06% |
Gaudium IVF & Women Health Competitors Screener - Peer Comparison
Screen GAUDIUMIVF competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 27,045 | 52.67 | 2,763 | 8.15% | 510 | 62.76 |
| Vijaya Diagnostic Centre | 14,033 | 79.42 | 814 | 16.36% | 182 | 76.26 |
| Metropolis Healthcare | 10,654 | 57.48 | 1,646 | 22.25% | 185 | 62.39 |
| Thyrocare Technologies | 7,186 | 45.25 | 829 | 18.06% | 156 | 64.76 |
| Nephrocare Health Services | 6,487 | 90.68 | 770 | 33.97% | 67 | 75.08 |
| Krsnaa Diagnostics | 1,833 | 23.53 | 743 | 16.70% | 78 | 45.23 |
| Suraksha Diagnostic | 1,562 | 49.20 | 256 | 15.11% | 31 | 64.76 |
| 3B BlackBio DX | 1,163 | 20.25 | 112 | 28.72% | 48 | 56.71 |
| Health X Platform | 880 | 32.79 | 1,171 | -18.47% | -134 | 52.97 |
| One Global Service Provider | 848 | 14.01 | 148 | 134.60% | 19 | 39.94 |
Gaudium IVF & Women Health Company Announcements - News Screener
Screen GAUDIUMIVF latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-04-16 | Clarification On Price Movement | - |
| 2026-04-16 | Clarification sought from Gaudium IVF and Women Health Ltd | - |
| 2026-04-15 | Intimation Regarding Change Of Corporate Identification Number Of The Company | - |
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-07 | Gaudium IVF And Women Health Limited Has Updated The Exchange On The Query Received From BSE Limited Vide Its Email Dated April 07 2026 Seeking Additional Details For Corporate Announcement Dated April 06 2026 Filed Under Regulation 30 Of SEBI (LODR) Regu | - |
| 2026-04-06 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) | - |
| 2026-04-01 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-01 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 ( "Listing Regulations") | - |
| 2026-03-28 | Closure of Trading Window | - |
| 2026-03-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-18 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-18 | Board Meeting Outcome for Board Meeting Outcome For Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-03-18 | Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-03-12 | Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-03-02 | Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015 | - |
| 2026-03-02 | Intimation Under Regulation 7(1) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) | - |
| 2026-03-02 | Intimation Under Regulation 6(1) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-02 | Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations") | - |